What is AceCann?
AceCann is a pharmaceutical-grade medical cannabis company founded in 2019 and based in Lisbon, Portugal. The company's mission is to develop consistent, high-quality products that provide patients with access to life-changing innovation, enabling healthier and longer lives. AceCann distinguishes itself within the rapidly expanding medical cannabis sector through its meticulous production processes, adhering to the highest pharmaceutical standards.
How much funding has AceCann raised?
AceCann has raised a total of $15M across 1 funding round:
Angel/Seed
$15M
Angel/Seed (2021): $15M with participation from Chris Mayle, Frank Cid, Casa Verde Capital, Sebastian de la Rosa, Marc Gare, and Lince Capital
Key Investors in AceCann
Casa Verde Capital
Casa Verde Capital is a leading venture capital firm exclusively focused on the cannabis industry, investing in scalable businesses led by world-class management teams that address long-term market needs.
Lince Capital
Lince Capital is a company specializing in financial solutions such as factoring, operating in the São Caetano do Sul region.
What's next for AceCann?
The recent major strategic investment signals a pivotal growth phase for AceCann. This capital infusion is expected to fuel further development and scaling of its pharmaceutical-grade medical cannabis products. With a clear focus on quality and patient access, AceCann is well-positioned to capitalize on the evolving global cannabis market, potentially expanding its reach and therapeutic offerings.
See full AceCann company page
